Triapine(Triapine) - 药物靶点：RNRs_在研适应症：腺鳞癌，宫颈鳞状细胞癌，鳞状细胞癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Triapine、3-AP、NSC#663249

+ [5]

靶点

RNRs

作用方式

抑制剂

作用机制

RNR抑制剂(核糖核苷酸还原酶复合体抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病其他疾病+ [3]

在研适应症

腺鳞癌宫颈鳞状细胞癌鳞状细胞癌+ [12]

非在研适应症

腺泡细胞癌急性早幼粒细胞白血病食管腺癌+ [60]

原研机构

Nanotherapeutics, Inc.

在研机构

National Cancer Institute

Nanopharmaceutics, Inc.

Nanotherapeutics, Inc.

非在研机构

Vion Pharmaceuticals, Inc.

权益机构

Resilience Government Services, Inc.

Trethera Corp.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C7H9N5S

InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N

CAS号143621-35-6

关联

34

项与 Triapine 相关的临床试验

NCT06860594

/ Not yet recruiting临床1期IIT

A Phase I Trial Combining Triapine With Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

开始日期2025-06-04

申办/合作机构

National Cancer Institute

NCT06410248

/ Active, not recruiting临床1期IIT

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

开始日期2024-07-23

申办/合作机构

Northwestern University

[+2]

NCT05724108

/ Recruiting临床2期IIT

A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.

开始日期2023-08-30

申办/合作机构

National Cancer Institute

100 项与 Triapine 相关的临床结果

登录后查看更多信息

100 项与 Triapine 相关的转化医学

登录后查看更多信息

100 项与 Triapine 相关的专利（医药）

登录后查看更多信息

409

项与 Triapine 相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

Article

作者: Randall, Leslie M ; Vargo, John ; Kohn, Elise C ; Orr, Brian ; Courtney-Brooks, Madeleine ; Ivy, S Percy ; Mahdi, Haider ; Behr, Sarah ; Lin, Yan ; Fabian, Denise ; Beriwal, Sushil ; Gallion, Holly ; Richardson, Debra L ; Chu, Edward ; Beumer, Jan H ; Kunos, Charles ; Huang, Marilyn ; Taylor, Sarah E ; Ueland, Frederick ; Olawaiye, Alexander B ; Girda, Eugenia ; Sullivan, Stephanie A ; Chauhan, Aman ; Cooper, Kristine L ; Christner, Susan M

BACKGROUND:

The addition of IV triapine to chemoradiation appeared active in phase I and II studies but drug delivery is cumbersome. We examined PO triapine with cisplatin chemoradiation.

METHODS:

We implemented a 3 + 3 design for PO triapine dose escalation with expansion, starting at 100 mg, five days a week for five weeks while receiving radiation with weekly IV cisplatin for locally advanced cervical or vaginal cancer. Maximum tolerated dose (MTD), dose limiting toxicity (DLT), adverse events, pharmacokinetics (PK), pharmacodynamics (PD), and metabolic complete response (mCR) were assessed.

RESULTS:

19/21 patients were DLT evaluable. DLTs included grade 4 neutropenia (n = 2), leukopenia (n = 2), lymphopenia (n = 2), and hypokalemia (n = 1). Grade 3 toxicities at least possibly related were as expected for cisplatin chemoradiation: lymphopenia (n = 12), anemia (n = 10), neutropenia (n = 4), leukopenia (n = 8), decreased platelets (n = 2), hypertension (n = 1), and hyponatremia (n = 1). MTD and RP2D were established at 100 mg. 8/13 evaluable patients had a mCR. Triapine had a bioavailability of 59%. Methemoglobin levels correlated with triapine exposure. Smoking almost doubled CYP1A2 mediated triapine clearance.

CONCLUSIONS:

Oral triapine is safe when given with cisplatin chemoradiation, convenient, bioavailable. Exposure is negatively impacted by smoking, and methemoglobin is a biomarker of exposure.

CLINICAL TRIAL REGISTRATION:

NCT02595879.

2025-04-01·GYNECOLOGIC ONCOLOGY

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial

Article

作者: Feddock, Jonathan M ; Deng, Wei ; Mell, Loren K ; Chino, Junzo P ; Monk, Bradley J ; Amarnath, Sudha R ; Arend, Rebecca C ; Walker, Joan L ; Santos-Reyes, Luis Javier ; Kunos, Charles M ; Ghamande, Sharad A ; Albuquerque, Kevin ; Lea, Jayanthi S ; Jegadeesh, Naresh ; Chon, Hye Sook ; Aghajanian, Carol ; DiSilvestro, Paul ; Richardson, Debra L ; Donnelly, Eric ; Mayadev, Jyoti ; Holman, Laura L ; MacKay, Helen ; Gao, Lei ; Quick, Allison M ; Lowenstein, Jessica ; Leath, Charles A

BACKGROUND:

Cisplatin-based chemoradiation (CRT) plus brachytherapy for locally advanced cervical cancer (LACC) is standard. Intrinsic overexpression of ribonucleotide reductase (RNR) may enhance DNA damage repair from CRT. We report on outcomes of adding RNR inhibitor, triapine (T), to CRT.

METHODS:

NRG-GY006 is an open-label randomized phase III trial. FIGO 2009 LACC (stages IB2, II, IIIB or IVA) without para-aortic nodal involvement or stages II-IV vaginal cancer were eligible. Random assignment to CRT or in combination with thrice-weekly T (CRT + T) occurred. Radiation consisted of either 3D conformal (3DCRT) or image-guided intensity modulated RT (IG-IMRT) followed by intracavitary brachytherapy. Primary endpoint was overall survival (OS). Progression-free survival (PFS) was secondary. Exploratory endpoints included complete metabolic response rate on post treatment PET/CT imaging and comparative toxicity and outcomes for 3DCRT vs. IG-IMRT.

FINDINGS:

Four-hundred-fifty patients were randomized including 448 eligible (224 in CRT and 224 in CRT + T). Median age was 47 (range 23-85). The majority had cervical cancer (93.3 %) with squamous histology (82 %). 52 % had FIGO stage II disease. Racial/ethnic distribution included non-Hispanic white (53.8 %), black (15.2 %) and Hispanic/Latina (22.5 %). At randomization, IG-IMRT was planned in 74.3 % and HDR brachytherapy in 98.2 %. No differences in Grade 3-5 toxicities were observed: CRT: 52 % and CRT + T: 49 %, with two G5 toxicities (cardiac arrest and acidosis) in the CRT + T arm. The median patient follow-up was 28 months (IQR 15-45). HR for death was 1.018 (95 % CI 0.634-1.635) while HR for progression was 1.021 (95 % CI 0.694-1.501).

INTERPRETATION:

Triapine added to CRT did not improve OS.

2025-02-01·TOXICOLOGY

Opposing effects of mycotoxins alternariol and deoxynivalenol on the immunomodulatory effects of oxaliplatin and triapine

Article

作者: Kowol, Christian R ; Gufler, Judith ; Hager, Sonja ; Heffeter, Petra ; Marko, Doris

Mycotoxin occurrence in food worldwide is estimated to increase due to climate change. Moreover, studies on how these food contaminants interfere with medications and especially anticancer therapies are rare. With the rise of anticancer immunotherapies, particularly mycotoxins with immunomodulatory activity, such as alternariol (AOH) or deoxynivalenol (DON), are of great concern. Both mycotoxins interfere with the pro-inflammatory nuclear factor kappa B (NF-κB) pathway in myeloid cells. This pathway not only plays an important role in the anticancer immune response but also inflammatory side effects induced by chemotherapeutic drugs. Consequently, the aim of this study was to investigate possible beneficial or detrimental immunomodulatory interactions between these mycotoxins and anticancer drugs. To assess the combined influence of mycotoxins and anticancer therapies on immune cell stimulation, THP-1 NF-κB reporter cells were utilized as monocytes as well as differentiated and polarized macrophages. Parameters for activation (NF-κB activity and protein expression), differentiation (CD14 and CD71 surface marker expression) and polarization (interleukin 10 (IL10), interleukin 8 (CXCL8), tumor necrosis factor α (TNF), prostaglandin-endoperoxide synthase 2 expression and CXCL8 secretion) were assessed upon combinatory treatment. Both mycotoxins affected the immunostimulatory effects of the pre-selected anticancer drugs oxaliplatin and triapine, although in opposing directions. While AOH generally suppressed a drug-induced activation and increased anti-inflammatory IL10 levels, DON potentiated activation and pro-inflammatory markers, such as CXCL8 and TNF in immune cells. In conclusion, AOH and DON have the potential to alter the immunological effects of anticancer therapies, which should be considered during therapy as well as in their future risk assessment.

4

项与 Triapine 相关的新闻（医药）

2024-05-14

·PRNewswire

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Patients with Recurrent Glioblastoma

ALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma" (ClinicalTrials.gov Identifier: NCT06410248). The primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ). Secondary objectives include evaluation of the safety profile of Triapine® in combination with temozolomide (TMZ), progression-free survival (PFS), overall survival (OS), overall response rate (ORR) per RANO criteria, and quality of life per FACT-Br. The study will recruit 40-45 patients with an established diagnosis of recurrent glioblastoma, and there will be an exploratory arm to investigate drug delivery into brain tumor tissue and target engagement in a cohort who are surgical candidates for re-resection of recurrent glioblastoma. Funding for the study is provided by BrainUp. Oral Triapine® has been shown to be safe, tolerable, and convenient in multiple clinical studies. Ribonucleotide Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with Triapine® may overcome chemoresistance and improve the clinical efficacy of TMZ therapy. Preliminary research from Dr. Atique Ahmed's lab at Northwestern University has uncovered a critical factor that helps glioblastoma, an aggressive brain cancer, resist chemotherapy treatment. About the Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer Institute-designated Comprehensive Cancer Center located on Northwestern Memorial Hospital's downtown medical campus in the Streeterville neighborhood of Chicago, Illinois, United States. About BrainUp BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp after their only child Olivia, was diagnosed 10 years ago with a Glioblastoma at the age of 22 years old. She died on April 19, 2014. The Kresachs formed BrainUp to fund brain cancer research. They have an annual run/walk to raise money for brain cancer research. They have funded over 1.2 million dollars supporting brain cancer research and trials at Chicago healthcare institutions. BrainUp is the financial supporter of Karan Dixit, M.D. (PI) and Atique Ahmed, Ph.D of Northwestern University Chicago, Illinois. To learn more about BrainUp, visit brainup.ngo About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. (OTC: TGRP) James D. Talton, Ph.D. President and Chief Executive Officer 386-401-6304 SOURCE Nanopharmaceutics, Inc.

临床1期寡核苷酸

2022-11-02

·PRNewswire

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 [email protected] SOURCE Nanopharmaceutics, Inc.

放射疗法

2022-11-02

·BioSpace

Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the NCI Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy with and without Triapine®

ALACHUA, Fla., Nov. 2, 2022 /PRNewswire/ -- Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, today announced completion of patient enrollment in the 450 patient Phase 3 clinical study sponsored by the NCI, part of the National Institutes of Health, and led by NCI funded network group, NRG Oncology, with participation of the NCI National Clinical Trials Network (NCTN), "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal," (NRG-GY006, ClinicalTrials.gov Identifier: NCT02466971). The randomized phase 3 trial is evaluating radiation therapy and cisplatin with Nanopharmaceutics' proprietary formulation of Triapine® compared to the standard radiation therapy and cisplatin, alone, in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with Triapine® Injection in treating cervical or vaginal cancer. 450 patients were enrolled in the study, which was performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceutics. About Triapine® Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis. About Nanopharmaceutics, Inc. Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Contact: Nanopharmaceutics, Inc. James D. Talton, Ph.D. President and Chief Executive Officer 352-401-6304 jtalton@nanopharmaceutics.com View original content: SOURCE Nanopharmaceutics, Inc.

放射疗法

100 项与 Triapine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11940

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺鳞癌	临床3期	美国	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
腺鳞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
宫颈鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	美国	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	加拿大	National Cancer Institute	2016-05-10
鳞状细胞癌	临床3期	波多黎各	National Cancer Institute	2016-05-10
子宫颈腺癌	临床3期	美国	National Cancer Institute	2016-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02595879 (ETCTN 9892, Pubmed \| Cancer Chemother Pharmacol)	临床1/2期	阴道腺癌 \| 局部晚期宫颈癌 methemoglobin levels \| smoking \| CYP1A2	21	Oral Triapine 100 mg	顧齋艱鹹鏇壓壓艱齋襯(範壓選觸鬱鏇艱淵淵鏇) = almost doubled CYP1A2 mediated triapine clearance 壓獵鬱廠壓餘簾壓構餘 (廠選築觸願構鹹鹽願築 ) 更多	积极	2025-12-01
NCT02595879 (ETCTN 9892, CTgov)	临床1期	腺鳞癌 \| 阴道腺癌 \| 局部晚期宫颈癌 ... 更多	21	triapine (All Participants)	遞築窪襯繭糧鏇壓壓遞 = 窪憲積積築積構繭憲夢蓋築願積鏇鏇願衊積鏇 (齋觸簾膚構範壓簾憲壓, 範範蓋衊鏇繭壓繭憲顧 ~ 鏇膚積網鬱衊壓繭鑰構)	-	2024-10-16
NCT02595879 (ETCTN 9892, CTgov)	临床1期	腺鳞癌 \| 阴道腺癌 \| 局部晚期宫颈癌 ... 更多	21	Triapine (Triapine (100mg) + Chemoradiation))	觸襯糧餘襯鏇範鏇網壓 = 築齋構蓋襯鬱餘壓夢遞顧襯築鹽遞淵鑰簾蓋選 (遞齋築簾夢積鹽齋選顧, 遞鏇獵餘窪襯獵艱觸淵 ~ 遞鹹製獵選繭鑰艱壓醖) 更多	-	2024-10-16
ASTRO2024	N/A	胶质母细胞瘤	-	Triapine	積醖願鹽艱積獵襯積選(遞窪蓋鬱鑰淵簾繭範獵) = 鹹鹽築鏇獵醖範繭糧願鏇艱襯衊糧膚願鏇築觸 (簾鹽夢膚壓網鏇壓廠糧 )	-	2024-10-01
NCT02466971 (NRG-GY006, CTgov)	临床3期	腺鳞癌 \| 阴道腺癌 \| 宫颈鳞状细胞癌 ... 更多	450	Intensity-Modulated Radiation Therapy+cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy))	願顧蓋醖壓膚艱範積鏇 = 衊衊壓鹹廠淵齋簾願廠糧網鹹膚觸蓋選窪齋餘 (觸鹽膚齋簾願艱簾構鹽, 鹽窪顧選鹽構壓遞鬱鹹 ~ 壓艱範餘餘範繭鏇齋壓) 更多	-	2024-01-05
NCT02466971 (NRG-GY006, CTgov)	临床3期	腺鳞癌 \| 阴道腺癌 \| 宫颈鳞状细胞癌 ... 更多	450	Intensity-Modulated Radiation Therapy+Triapine+cisplatin (Arm II (Cisplatin, IMRT or RT, Brachytherapy, Triapine))	願顧蓋醖壓膚艱範積鏇 = 築襯鏇獵夢憲顧積襯膚糧網鹹膚觸蓋選窪齋餘 (觸鹽膚齋簾願艱簾構鹽, 窪獵鹹衊遞積淵襯艱廠 ~ 鏇襯範範積觸憲範繭繭) 更多	-	2024-01-05
NCT02466971 (NRG-GY006, ASCO2023)	临床3期	阴道肿瘤 \| 局部晚期宫颈癌	448	Cisplatin + RT	遞構夢膚鏇膚積夢淵憲(衊鹽膚窪窪顧淵蓋蓋顧): HR = 1.018 (95% CI, 0.634 ~ 1.635) 更多	不佳	2023-05-31
NCT02466971 (NRG-GY006, ASCO2023)	临床3期	阴道肿瘤 \| 局部晚期宫颈癌	448	Cisplatin + RT + Triapine		不佳	2023-05-31
NCT04234568 (AACR2023) 人工标引	临床1期	胃肠胰神经内分泌肿瘤 SSTR Expression	31	triapine+Lutetium Dotatate LU-177	襯齋顧遞鹽襯網遞獵醖(壓艱範製觸鹹鏇鏇網鏇) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. 夢鏇網糧夢獵憲憲憲觸 (淵願積顧齋糧網艱壓鹹 ) 更多	积极	2023-04-14
NCT04234568 (ASCO_GI2023) 人工标引	临床1期	SSTR阳性胃肠胰神经内分泌肿瘤 SSTR1 Expression	31	triapine+lutetium Lu-177 dotatate	範選鏇憲淵廠積夢鹽鹽(夢蓋膚積壓淵遞糧淵構) = 齋鏇衊獵觸構憲衊壓構範鏇選網網衊窪願淵築 (鏇鑰膚鏇齋願簾繭鏇網 ) 更多	积极	2023-01-24
NCT04234568 (ASCO2020)	临床1期	神经内分泌肿瘤一线	29	Triapine and Lutetium Lu 177 Dotatate	鏇願願餘範網鹹鑰窪鬱(鏇繭鹽夢製顧蓋齋憲壓) = 鹽艱蓋選遞繭繭範餘鹽艱糧遞選艱構蓋製鬱膚 (製壓鏇選選網鏇襯壓構 )	-	2020-05-25
NCT02466971 (Pubmed \| Front Oncol) 人工标引	临床2期	阴道肿瘤 \| 子宫颈疾病	26	cisplatin+Radiotherapy+triapine	窪齋膚衊餘願獵願艱憲(鹽鹹襯繭鏇蓋鬱願鑰齋) = 艱鬱選夢餘淵窪衊構蓋窪廠鬱網襯鹽艱願蓋淵 (窪壓簾繭鬱窪網築憲鏇 ) 更多	积极	2019-10-15
NCT02466971 (Pubmed \| Front Oncol) 人工标引	临床2期	阴道肿瘤 \| 子宫颈疾病	26	cisplatin+Radiotherapy	窪齋膚衊餘願獵願艱憲(鹽鹹襯繭鏇蓋鬱願鑰齋) = 鹹構淵鬱夢觸夢簾繭構窪廠鬱網襯鹽艱願蓋淵 (窪壓簾繭鬱窪網築憲鏇 ) 更多	积极	2019-10-15
NCT00016874 (Pubmed \| Front Oncol) 人工标引	临床1期	实体瘤	13	cisplatin+paclitaxel+triapine	壓廠鏇夢遞願齋蓋醖鹽(觸襯觸範糧憲構餘獵醖) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) 獵繭繭顧願構鏇願膚製 (蓋獵製淵鬱鹹齋憲衊襯 ) 更多	积极	2017-04-04